modelTetracaine
Extends from Pharmacolibrary.Drugs.ATC.S.S01HA03.
Information
| name: | Tetracaine | |
| ATC code: | S01HA03 | route: | topical |
| compartments: | 1 | |
| dosage: | 1 | mg |
| volume of distribution: | 1.5 | L |
| clearance: | 40 | L/h |
| other parameters in model implementation | ||
Tetracaine is an ester-type local anesthetic used primarily for topical anesthesia in ophthalmology, dentistry, and ENT procedures. It acts by blocking sodium channels, inhibiting nerve impulse conduction. It is approved for topical use and continues to be used for local anesthesia, particularly for eye procedures.
Pharmacokinetics
Estimated pharmacokinetic parameters for adult human after ocular or topical administration. No published studies reporting compartmental pharmacokinetic models in humans are available. Parameters are estimated based on general physico-chemical properties, route of administration, and analogous local anesthetics.
References
O'Brien, L, et al., & Koren, G (2005). A critical review of the topical local anesthetic amethocaine (Ametop) for pediatric pain. Paediatric drugs 7(1) 41–54. DOI:10.2165/00148581-200507010-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15777110
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)